We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications.
- Authors
Gonzalez-Bocco, Isabel H; Aleissa, Muneerah M; Zhou, Eric; Manne-Goehler, Jennifer; Koo, Sophia; Cheng, Matthew P; Marty, Francisco M
- Abstract
Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73), drug intolerability (1/5 vs 4/11; P = 1), or 90-day mortality (0/13 vs 1/17; P = 1) in patients receiving clarithromycin vs azithromycin.
- Publication
Open Forum Infectious Diseases, 2022, Vol 9, Issue 1, p1
- ISSN
2328-8957
- Publication type
Article
- DOI
10.1093/ofid/ofab582